Physician profile
Heidi Gast
NPI 1811232366
$2,098.77
in general payments reported to CMS, 2019-2025
28 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $352 · 2022: $401 · 2023: $642 · 2024: $270 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,344.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $485.53 | 2021-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Silk Road Medical, INC. | $122.93 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| E.R. Squibb & Sons, L.L.C. | $121.96 | 2025 | Zeposia |
| Sk Life Science, INC. | $117.72 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $115.88 | 2021-2025 | Airsupra |
| Abbvie INC. | $100.13 | 2023 | |
| Bard Peripheral Vascular, INC. | $89.27 | 2025 | Rotarexs 6 F X 135 Cm |
| Medtronic, INC. | $87.35 | 2023 | Venaseal |
| United Therapeutics Corporation | $76.13 | 2021-2023 | Tyvaso |
| Novo Nordisk INC | $75.64 | 2022 | |
| Alkermes, INC. | $69.73 | 2022 | |
| Genzyme Corporation | $69.20 | 2022-2025 | |
| Baxter Healthcare | $68.25 | 2023-2024 | Hillrom - Vest System Model 105 Home Care |
| Edwards Lifesciences Corporation | $63.26 | 2022 | |
| Neurelis, INC. | $58.48 | 2024 | Valtoco |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $54.59 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $48.00 | 2021-2025 | Opsumit |
| Lilly USA, LLC | $43.43 | 2022 | |
| Advanced Respiratory, INC | $40.00 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $37.79 | 2024-2025 | Lumryz |
| Mylan Specialty L.P. | $33.02 | 2021-2023 | Yupelri |
| Harmony Biosciences LLC | $25.72 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.42 | 2024 | |
| Axsome Therapeutics, INC. | $16.95 | 2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $16.23 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.95 | 2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.68 | 2021 | |
| Viatris Specialty LLC | $13.53 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Gast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.